Edgewise Therapeutics (EWTX) Cash & Equivalents (2020 - 2026)

Edgewise Therapeutics has disclosed Cash & Equivalents across 7 years of filings, most recently posting $499.6 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $499.6 million, up 14.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $499.6 million (up 14.48% YoY), and the FY2025 annual result was $61.1 million, up 46.76% from the prior year.
• Cash & Equivalents came in at $499.6 million for Q1 2026 at Edgewise Therapeutics, up from $61.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $594.0 million in Q2 2025 to a low of $22.0 million in Q4 2022.
• The 5-year median for Cash & Equivalents is $248.4 million (2022), against an average of $229.7 million.
• Across the five-year window, Cash & Equivalents sank 90.77% in 2024 and jumped 1341.98% in 2025, its largest moves.
• Edgewise Therapeutics' Cash & Equivalents stood at $22.0 million in 2022, then surged by 291.47% to $86.1 million in 2023, then slumped by 51.61% to $41.7 million in 2024, then soared by 46.76% to $61.1 million in 2025, then jumped by 717.03% to $499.6 million in 2026.
• The last three Cash & Equivalents figures came in at $499.6 million (Q1 2026), $61.1 million (Q4 2025), and $46.0 million (Q3 2025), per Business Quant data.